康华生物新一届董事会亮相 国资基金完成关键治理部署

Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. has officially announced a new board of directors and executive team, marking a new development phase focused on governance optimization and strategic upgrades [1][4] Group 1: Governance Structure - The new board consists of 11 directors, including 7 non-independent and 4 independent directors, creating a "7+4" decision-making structure that emphasizes strategic collaboration and professional governance [1][2] - Liu Dawei has been elected as the chairman, while Wang Zhentao serves as the vice chairman, ensuring a smooth transition and continuity in business development [1][2] - The independent directors bring expertise from various fields such as industry, finance, and law, enhancing the company's decision-making and risk management capabilities [2] Group 2: Strategic Implementation - The new governance team aims to establish an efficient "strategy-execution" mechanism to ensure the successful implementation of the company's strategies in marketing, R&D, and operations [2] - Kanghua Biological has completed a marketing structure transformation and will focus on reorganizing its R&D pipeline and capital operations to improve overall efficiency and market competitiveness [2][3] Group 3: Industry Development - The restructuring of governance is a critical step in implementing the company's future strategic blueprint, focusing on both "mature products" and "innovative pipelines" for further development [3] - The company plans to maintain its market position for established products while accelerating the development and commercialization of innovative vaccines, creating new growth points [3] - The new organizational structure will leverage resources from both Shanghai and Chengdu to enhance the integration of R&D, clinical, and commercialization processes [3] Group 4: Industry Benchmarking - The comprehensive upgrade of the board and executive team signifies a shift from founder-driven to a systematic and professional-driven approach [4] - This governance practice not only injects momentum into Kanghua Biological's future development but also provides a replicable model for the integration and upgrading of the Chinese biopharmaceutical industry [4]